- 免疫原性
- レベル
- 世界初
- 中国工程院
- 令和
- 免疫反応
- 楊志剛
- 王迪
- 確認
- 筋肉注射
「免疫原」の写真・映像
- 提供元
- 日付
- 種類
- 向き
- カテゴリ
- 色
- 提供元
- 日付
- 24時間以内 0
- 48時間以内 0
- 72時間以内 0
- 7日以内 0
- 30日以内 0
- 1年以内 3
- 期間を指定 17
- 日付指定なし 17
- 種類
- 写真 16
- グラフィック 0
- 映像 1
- 向き
- 縦 8
- 横 9
- 正方形 0
- カテゴリ
- ニュース
- スポーツ
- エンターテインメント
- 教育向け
- カテゴリ指定なし
- 色
- カラー 17
- モノクロ 0
- 古い順
- 1
- 古い順
2016年08月02日Zika Virus Investigational DNA VaccineA healthy volunteer receives the NIAID Zika virus investigational DNA vaccine as part of an early-stage trial to test the vaccine‘s safety and immunogenicity. This is the first administration of this vaccine in a human. Credit: NIAID. .、クレジット：ＩＭＡＧＥ ＰＯＩＮＴ ＦＲ ／ ＮＩＨ ／ ＮＩＡＩＤ／Ｕｎｉｖｅｒｓａｌ Ｉｍａｇｅｓ Ｇｒｏｕｐ／共同通信イメージズ
商品コード: 2021030103437
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082704529
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082704725
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082704667
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082704573
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082704582
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082700912
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082704652
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082704790
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082704788
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082700939
2020年08月25日Pfizer Claims 90 Percent Efficiency with COVID-19 VaccineAugust 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020111007796
2020年08月25日Covid-19 Vaccine testing begins in U.S.August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット：©Ｒｏｂｉｎ Ｒａｙｎｅ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082704999
2020年08月26日Company logos displayed on smartphone in Brazil - 26 Aug 2020July 4, 2020, Brazil: In this photo illustration the ImmunoGen logo seen displayed on a smartphone. (Credit Image: © Rafael Henrique/SOPA Images via ZUMA Wire)、クレジット：©Ｒａｆａｅｌ Ｈｅｎｒｉｑｕｅ／ＳＯＰＡ Ｉｍａｇｅｓ ｖｉａ ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2020082801688
01:12.862021年07月31日「新華社」中国製吸入型ワクチンの第１相臨床試験結果、英医学誌に発表中国工程院の陳薇（ちん・び）院士（アカデミー会員）率いる科学研究チームが開発した噴霧吸入型の新型コロナウイルスワクチンの第１相臨床試験データがこのほど、英医学誌「ランセット感染症」の電子版に掲載された。新型コロナワクチンの粘膜免疫に関する臨床試験の結果が公開されるのは世界初となる。臨床試験が行われたのはアデノウイルスベクターワクチンで、第１相試験の結果、高い安全性と免疫原性が確認された。１回分の分量は筋肉注射の５分の１程度で済み、免疫反応のレベルは筋肉注射１回分に相当するという。（記者／王逸濤、楊志剛、張振威、王迪、王静怡） ＝配信日： ２０２１（令和３）年７月３１日、クレジット：新華社／共同通信イメージズ
商品コード: 2021073110467
2022年01月13日AstraZeneca COVID-19 Vaccine BoosterJanuary 13, 2022, Asuncion, Paraguay: Illustration: A syringe is seen in front of AstraZeneca logo, visual representation of virus and vials labeled ‘‘COVID-19 Vaccine‘‘. AstraZeneca has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. The new data showed increased antibody response against Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, following third dose booster. Additional analysis showed increased antibody response to Omicron after a third dose. (Credit Image: © Andre M. Chang/ZUMA Press Wire)、クレジット：©Ａｎｄｒｅ Ｍ． Ｃｈａｎｇ／ＺＵＭＡ Ｐｒｅｓｓ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2022011408894
2022年01月13日AstraZeneca COVID-19 Vaccine BoosterJanuary 13, 2022, Asuncion, Paraguay: Illustration: A syringe is seen in front of AstraZeneca logo, visual representation of virus and vials labeled ‘‘COVID-19 Vaccine‘‘. AstraZeneca has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. The new data showed increased antibody response against Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, following third dose booster. Additional analysis showed increased antibody response to Omicron after a third dose. (Credit Image: © Andre M. Chang/ZUMA Press Wire)、クレジット：©Ａｎｄｒｅ Ｍ． Ｃｈａｎｇ／ＺＵＭＡ Ｐｒｅｓｓ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2022011406141
- 1
